FDA Concludes Entire Antiepileptic Category Poses Suicidality Risk

FDA is concluding from its statistical analysis of suicidality for antiepileptic drugs that the entire therapeutic category poses an increased risk of suicidal behavior or ideation. But there may be a silver lining for sponsors within the data